Oncology Medical News about palonosetron

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy
Annals of Oncology, 06/29/09

Maemondo M et al. - Palonosetron at doses of 0.25 and 0.75 mg was shown to be effective in preventing chemotherapy-induced nausea and vomiting with high CR rates of patients treated with HEC in Japan. All tested doses of palonosetron were tolerated well.

<< Previous
Reintroduction of CEBPA in MN1-overexpressing hematopoietic cells...

Next >>
Retrospective and prospective studies of hepatitis B virus...

Palonosetron in Prevention of Nausea and Vomiting After Highly Emetogenic Chemotherapy Before Haematopoietic Stem Cell Transplantation--Single Center Experience
Transplantation Proceedings, 11/16/09 Relevance Score: 83%